ArticleCancers2023

TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS).

Luc M Berclaz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.